 SHANGHAI, China and GAITHERSBURG, Md., March 19, 2021 GLOBE NEWSWIRE -- I-Mab the Company Nasdaq: IMAB, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today filed a prospectus supplement with the Securities and Exchange Commission the SEC to register 19,050,555 ordinary shares, including ordinary shares represented by American depositary shares ADSs of I-Mab, held by Gaoling Fund, L.P. and YHG Investment, L.P. collectively Hillhouse. Hillhouse acquired these ordinary shares pursuant to a series of subscription agreements dated September 3, 2020 through a private placement the PIPE Agreements. The Company is filing a shelf registration to register the aforementioned ordinary shares, including ordinary shares represented by ADSs, to satisfy contractual registration rights of Hillhouse in the PIPE Agreements. Currently, Hillhouse beneficially owns 22,492,602 ordinary shares of the Company, or 13.3 of the total outstanding ordinary shares. 